Evidence map›Paper›PMID 37338559›Full record

ArticleEuropean radiology2023

[

Kai Jannusch, Janna Morawitz, Bernd Schweiger, Daniel Weiss, Lars Schimmöller, Peter Minko, Ken Herrmann, Wolfgang P Fendler, Harald H Quick, Gerald Antoch and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kai JannuschDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Janna MorawitzDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Bernd SchweigerDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147, Essen, Germany.
Daniel WeissDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Lars SchimmöllerDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Peter MinkoDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, 45147, Essen, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, 45147, Essen, Germany.
Harald H QuickHigh-Field and Hybrid MR Imaging, University Hospital Essen, University Duisburg-Essen, 45147, Essen, Germany.
Gerald AntochDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Lale UmutluDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, 45147, Essen, Germany.
Julian KirchnerDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany. Julian.Kirchner@med.uni-duesseldorf.de.ORCID http://orcid.org/0000-0001-8224-3433
Nils-Martin BruckmannDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany.
Heinrich Heine University Düsseldorf · DEUniversity of Duisburg-Essen · DEDüsseldorf University Hospital · DEErwin L. Hahn Institute for Magnetic Resonance Imaging · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEvaluate the influence of an MRI contrast agent application on primary and follow-up staging in pediatric patients with newly diagnosed lymphoma using [

methodsA total of 105 [

resultsIn patient-based analysis, PET/MRI-1 and PET/MRI-2 both determined a correct IPNHLSS tumor stage in 90/105 (86%) exams. Region-based analysis correctly identified 119/127 (94%) lymphoma-affected regions. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy for PET/MRI-1 and PET/MRI-2 were 94%, 97%, 90%, 99%, 97%, respectively. There were no significant differences between PET/MRI-1 and PET/MRI-2.

conclusionsThe use of MRI contrast agents in [ CLINICAL RELEVANCE STATEMENT: This study gives a scientific baseline switching to a contrast agent-free [ KEY POINTS: • No additional diagnostic benefit of MRI contrast agents at [

Indexed as

Fluorodeoxyglucose F18LymphomaChildContrast MediaHumansMagnetic Resonance ImagingNeoplasm StagingPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificityContrast MediaFluorodeoxyglucose F18RadiopharmaceuticalsContrast mediaLymphomaMagnetic resonance imagingNeoplasm stagingPositron-emission tomography

Identifiers

PMID37338559
PMCPMC10598113
OpenAlexW4381308137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.